When TIGIT inhibition was combined with anti-PD-1 inhibition in vitro, it was found to enhance tumor antigen specific CD8+ T cell expansion and activity, as compared with anti-PD-1 inhibition alone [64]. This evidence concerns the gene PDCD1 and neoplasm.